吴崇明，汉族，中共党员，理学博士，研究员，博士生导师。毕业于中国科学院大学，博士学位，现任天津中医药大学中药学院药理教研室专任教师。

主要从事肠道微生物药物药理学研究。担任中国药理学会心血管药理专业委员会委员等。主讲《肠道微生物组与药理学》《科学研究的思维方法和训练》等课程。主持国家自然科学基金3项。以第一作者或通讯作者发表论文88篇，其中SCI收录论文73篇、被引3000余次。

承担科研项目情况：

主要代表性成果：

1. Zou L, et al. Gut microbiota-based discovery of Houttuyniae Herba as a novel prebiotic of Bacteroides thetaiotaomicron with anti-colitis activity. Biomed Pharmacother. 2024;172:116302. (IF:7.5)(中科院1区)(通讯作者）

2. Zhong S, et al, The gut microbiota‐aromatic hydrocarbon receptor (AhR) axis mediates the anticolitic effect of polyphenol‐rich extracts from Sanghuangporus. iMeta 2024;e180. (IF:23.7)(国内高起点期刊)(通讯作者）

3. Xu W, et al. Therapeutic potential of dietary nutrients and medicinal foods against metabolic disorders: Targeting Akkermansia muciniphila. Food Frontiers 2024; 1-21. (5year-IF:10.0)(国内高起点期刊)(通讯作者）

4. Wang X, et al. Oral bacteriome and mycobiome of patients with idiopathic membranous nephropathy with different tongue coatings treated with a Chinese herbal formula. J Ethnopharmacol. 2024, In press. (IF:5.4)(中科院1区)(通讯作者)

5. Xu W, et al. Strain-level screening of human gut microbes identifies Blautia producta as a new anti-hyperlipidemic probiotic. Gut Microbes. 2023;15(1):2228045. (IF:12.2)(中科院1区)(通讯作者）

6. Yang Z, et al. Gut microbiota and hypertension: association, mechanisms and treatment. Clin Exp Hypertens. 2023;45(1):2195135. (IF:12.3)(通讯作者)(ESI高被引论文)

7. Dong C, et al. Gut microbiota combined with metabolites reveals unique features of acute myocardial infarction patients different from stable coronary artery disease. J Adv Res. 2023;46:101-112. (IF:12.8)(通讯作者)(ESI高被引论文)

8. Yang Y, et al. The linkage of gut microbiota and the property theory of traditional Chinese medicine (TCM): Cold-natured and sweet-flavored TCMs as an example. J Ethnopharmacol. 2023 Apr 24;306:116167. (IF:5.4)(中科院1区)(通讯作者)

9. Yang Y, et al. Traditional Chinese medicines (TCMs) with varied meridians (Gui-Jing) differentially alleviate the adverse impact of Coptis chinensis on gut microbiota. J Ethnopharmacol. 2023 May 10;307:116256.   (IF:5.4)(中科院1区)(通讯作者)

10. Wu C, et al. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients. J Adv Res. 2022; 37:197–208. （IF:12.822)(中科院1区)(通讯作者)(ESI高被引论文)

11.  Li C, et al. Deep insights into the gut microbial community of extreme longevity in south Chinese centenarians by ultra-deep metagenomics and large-scale culturomics. NPJ Biofilms Microbiomes. 2022 Apr 19;8(1):28.（5YEAR-IF:9.67)(中科院1区)(通讯作者)(Nature小子刊)

12.  Chen R, et al. Orally administered Bi2S3@SiO2 core-shell nanomaterials as gastrointestinal contrast agents and their influence on gut microbiota. Mater Today Bio. 2022;13:100178.（IF:10.761)(中科院1区)(通讯作者）

13.  Wang X, et al. Structural modulation of gut microbiota during alleviation of experimental passive Heymann nephritis in rats by a traditional Chinese herbal formula. Biomed Pharmacother. 2022 Jan;145:112475.（IF:7.419)(中科院1区)(通讯作者）

14. Duan Y, et al. Marked shifts in gut microbial structure and neurotransmitter metabolism in fresh inmates revealed a close link between gut microbiota and mental health: A case-controlled study. Int J Clin Health Psychol. 2022;22(3):100323.（IF:5.9)(中科院1区)(通讯作者）

15. Yang Y and Wu C. Targeting Gut Microbial Bile Salt Hydrolase (BSH) by Diet Supplements: New Insights into Dietary Modulation of Human Health. Food Funct. 2022;13(14):7409-7422. (IF:6.317)(中科院1区)(通讯作者）

16. Yang Y, et al. Dual modulation of gut bacteria and fungi manifests the gut-based anti-hyperlipidemic effect of Coptidis Rhizoma. Biomed Pharmacother. 2022;153: 113542. （IF:7.419)(中科院1区)(通讯作者）

17. Yang Y, et al. The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression. Biomed Pharmacother. 2022;155:113749. （IF:7.419)(中科院1区)(通讯作者）

18. Li H, et al. Adenosine-rich extract of Ganoderma lucidum: a safe and effective lipid-lowering substance via regulating expression and modulation of PPAR signaling pathway. iScience. 2022 Sep 26;25(11):105214.（IF:6.107)(通讯作者)(Cell小子刊)

19. Yang Y, et al. The Gut Microbial Co-Abundance Gene Groups (CAGs) Differentially Respond to the Flavor (Yao-Wei) of Chinese Meteria Medica. Am J Chin Med. 2022, 50(7):1-22. (IF:6.005)(中科院1区)(通讯作者）

20. Zhang Y, et al. Laurolitsine ameliorates type 2 diabetes by regulating the hepatic LKB1-AMPK pathway and gut microbiota. Phytomedicine. 2022 Nov;106:154423. (IF:6.656)(中科院1区)(通讯作者）

21 Qiao J, et al. Perturbation of gut microbiota plays an important role in micro/nanoplastics-induced gut barrier dysfunction. Nanoscale 2021. 13(19):8806-8816 (IF:7.79)(中科院1区)（封面论文)(通讯作者)(ESI高被引论文)

22 Zhang X, et al. The Traditional Chinese Medicines differentially modulate the gut microbiota on the base of their natures (Yao-Xing). Phytomedicine 2021; 85:153496 (IF:6.66)(中科院1区) (通讯作者）

23. Qi G, et al. Cordycepin promotes browning of white adipose tissue through an AMP-activated protein kinase (AMPK)-dependent pathway. Acta Pharm Sin B. 2019 Jan;9(1):135-143. (IF:6.014，中科院1区) (通讯作者）

24. Wu C, et al. The pandanus tectorius fruit extract (PTF) modulates the gut microbiota and exerts anti-hyperlipidaemic effects. Phytomedicine. 2019;58: 152863. (IF:4.18，中科院1区) (通讯作者）

25. Li Y, et al.  The mulberry-derived 1-deoxynojirimycin (DNJ) inhibits high-fat diet (HFD)-induced hypercholesteremia and modulates the gut microbiota in a gender-specific manner. J Funct Foods. 2019; 52: 63-72. (IF:3.47，中科院1区)

26. Li J, et al. The Antihyperlipidemic Effects of Fullerenol Nanoparticles via Adjusting the Gut Microbiota in vivo. Part Fibre Toxicol 2018, 15(1):5. (5-year IF:9.628，中科院1区) (通讯作者）

27. Li J, et al. Oral administration of rutile and anatase TiO2 nanoparticles shifts mouse gut microbiota structure. Nanoscale. 2018;10(16):7736-7745. (IF:7.736，中科院1区) (通讯作者）

联系方式：cmwu@tjutcm.edu.cn